FDC Limited (FDC) fundamentals
FDC Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as FDC (ISIN INE258B01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What FDC Limited does
FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its products include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen Sodium, Miconazole Nitrate, Timolol Maleate, Amoxycillin + Clavulanic Acid, Rupatadine Fumarate, Salbutamol Sulphate, Kaolin Light/ Pectin, among others. The Company’s product offerings cover an extensive range of categories, including anti-infectives, gastrointestinal treatments, ophthalmic, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, respiratory care, gynecology, dermatology and analgesics. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
Valuation and market data
| Last close | ₹346.40 |
|---|---|
| Market capitalisation | ₹5,639 crore |
| Enterprise value | ₹5,661 crore |
| P/E (TTM) | 0.00 |
| Price to book | 2.47 |
| Price to sales (TTM) | 2.42 |
| Book value per share | ₹140.14 |
| Dividend yield | 144.34% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Aug 07 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹2,237 crore | ₹378 crore | ₹286 crore | 0.00 |
| Mar 2025 | ₹2,176 crore | ₹368 crore | ₹274 crore | 16.81 |
| Mar 2024 | ₹2,019 crore | ₹398 crore | ₹307 crore | 18.70 |
| Mar 2023 | ₹1,831 crore | ₹266 crore | ₹201 crore | 12.09 |
| Mar 2022 | ₹1,598 crore | ₹285 crore | ₹220 crore | 13.01 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 69.7% |
|---|---|
| Foreign institutions (FII) | 1.4% |
| Mutual funds | 6.3% |
| Other domestic institutions | 0.1% |
| Retail and others | 22.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.